|
JP5864546B2
(ja)
|
2010-05-07 |
2016-02-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
インダゾール
|
|
CA2841142C
(en)
|
2010-06-23 |
2020-12-15 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
BR112013005806B1
(pt)
|
2010-09-10 |
2022-05-10 |
Epizyme, Inc |
Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
|
|
JP5908493B2
(ja)
*
|
2010-12-01 |
2016-04-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
インドール
|
|
EP3323820B1
(en)
|
2011-02-28 |
2023-05-10 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
TW201733984A
(zh)
|
2011-04-13 |
2017-10-01 |
雅酶股份有限公司 |
經取代之苯化合物
|
|
AU2013203641B2
(en)
*
|
2011-04-13 |
2014-08-21 |
Epizyme, Inc. |
Aryl-or heteroaryl-substituted benzene compounds
|
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
CA2850570A1
(en)
*
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
CA2854447A1
(en)
*
|
2011-11-04 |
2013-05-10 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of treatment
|
|
US9206128B2
(en)
|
2011-11-18 |
2015-12-08 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
WO2013075084A1
(en)
|
2011-11-18 |
2013-05-23 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EA037918B1
(ru)
|
2011-12-21 |
2021-06-07 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
|
EP2953941B1
(en)
*
|
2013-02-11 |
2017-04-05 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
WO2013120104A2
(en)
|
2012-02-10 |
2013-08-15 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
KR102587175B1
(ko)
|
2012-03-12 |
2023-10-06 |
에피자임, 인코포레이티드 |
인간 ｅｚｈ2의 억제제 및 이의 사용 방법
|
|
US9932317B2
(en)
|
2012-03-19 |
2018-04-03 |
Imperial Innovations Limited |
Quinazoline compounds and their use in therapy
|
|
IL296199B2
(en)
*
|
2012-04-13 |
2024-12-01 |
Eisai R&D Man Co Ltd |
Salt form of a human hi stone methyltransf erase ezh2 inhibitor
|
|
US9562041B2
(en)
|
2012-05-16 |
2017-02-07 |
Glaxosmithkline Llc |
Enhancer of zeste homolog 2 inhibitors
|
|
JP2015522259A
(ja)
|
2012-06-14 |
2015-08-06 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
化学実体とそれらの標的分子の間の相互作用を評価するゲノム全域法
|
|
HK1208465A1
(en)
|
2012-08-28 |
2016-03-04 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
CA2884848C
(en)
*
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
|
CA2887243C
(en)
|
2012-10-15 |
2024-04-09 |
Epizyme, Inc. |
Methods of treating cancer
|
|
AU2013331380B2
(en)
*
|
2012-10-15 |
2018-03-22 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
AU2013371541B2
(en)
*
|
2012-12-13 |
2016-10-13 |
Glaxosmithkline Llc |
Enhancer of Zeste Homolog 2 inhibitors
|
|
WO2014100080A1
(en)
*
|
2012-12-19 |
2014-06-26 |
Glaxosmithkline Llc |
Combination
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
WO2014100665A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone bicyclic heteroaryl compounds
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
US9133189B2
(en)
|
2013-03-14 |
2015-09-15 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
AU2014260433A1
(en)
|
2013-03-14 |
2015-09-10 |
Epizyme, Inc. |
Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
|
|
US9447079B2
(en)
|
2013-03-14 |
2016-09-20 |
Epizyme, Inc. |
PRMT1 inhibitors and uses thereof
|
|
WO2014144659A1
(en)
|
2013-03-14 |
2014-09-18 |
Epizyme, Inc. |
Pyrazole derivatives as prmt1 inhibitors and uses thereof
|
|
HRP20202008T1
(hr)
|
2013-03-14 |
2021-02-19 |
Epizyme, Inc. |
Inhibitori arginin-metiltransferaze i njihove uporabe
|
|
WO2014153235A2
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
JP2016518336A
(ja)
|
2013-03-14 |
2016-06-23 |
エピザイム，インコーポレイティド |
Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用
|
|
US9365527B2
(en)
|
2013-03-14 |
2016-06-14 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2014153208A1
(en)
|
2013-03-14 |
2014-09-25 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
US9120757B2
(en)
|
2013-03-14 |
2015-09-01 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
US9745305B2
(en)
|
2013-03-15 |
2017-08-29 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
WO2014155301A1
(en)
*
|
2013-03-26 |
2014-10-02 |
Piramal Enterprises Limited |
Substituted bicyclic compounds as inhibitors of ezh2
|
|
WO2014161888A1
(en)
|
2013-04-03 |
2014-10-09 |
Janssen R&D Ireland |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
US9505745B2
(en)
|
2013-04-30 |
2016-11-29 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
RS57999B1
(sr)
|
2013-05-17 |
2019-01-31 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
EP3004096A1
(en)
*
|
2013-06-06 |
2016-04-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
ES2640386T3
(es)
*
|
2013-07-10 |
2017-11-02 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Potenciador de inhibidores del homólogo Zeste 2
|
|
ES2774749T3
(es)
|
2013-07-25 |
2020-07-22 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
|
EP3033334A1
(en)
|
2013-08-15 |
2016-06-22 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
|
AU2014337300B2
(en)
|
2013-10-16 |
2019-01-03 |
Eisai R&D Management Co., Ltd. |
Hydrochloride salt form for EZH2 inhibition
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
US9822103B2
(en)
|
2013-11-22 |
2017-11-21 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
KR20160128305A
(ko)
|
2014-02-05 |
2016-11-07 |
노비라 테라퓨틱스, 인코포레이티드 |
Hbv 감염의 치료를 위한 병용 요법
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
US20160340674A1
(en)
*
|
2014-02-10 |
2016-11-24 |
University Of Rochester |
Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases
|
|
EP3111222A1
(en)
|
2014-02-26 |
2017-01-04 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
US20170105997A1
(en)
*
|
2014-03-21 |
2017-04-20 |
Northwestern University |
Methods of treating cancer
|
|
CN105037360B
(zh)
*
|
2014-04-28 |
2016-08-17 |
四川大学 |
吡啶酮衍生物及其制备方法和用途
|
|
CN105017221B
(zh)
*
|
2014-04-30 |
2019-05-28 |
中国医学科学院药物研究所 |
苯并咪唑衍生物及其制法和药物组合物与用途
|
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
US20170217941A1
(en)
*
|
2014-06-25 |
2017-08-03 |
Epizyme, Inc. |
Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
|
|
CN107148419A
(zh)
*
|
2014-10-28 |
2017-09-08 |
葛兰素史密斯克莱知识产权（第2 号）有限公司 |
Zeste增强子同源物2抑制剂
|
|
KR20170081213A
(ko)
|
2014-11-06 |
2017-07-11 |
다나-파버 캔서 인스티튜트 인크. |
Ezh2 억제제 및 그의 용도
|
|
AR102767A1
(es)
|
2014-12-05 |
2017-03-22 |
Lilly Co Eli |
Inhibidores de ezh2
|
|
WO2016102493A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
|
EA032416B1
(ru)
*
|
2014-12-23 |
2019-05-31 |
Новартис Аг |
Соединения триазолопиримидина и их применения
|
|
EP3236962A2
(en)
|
2014-12-23 |
2017-11-01 |
University of Copenhagen |
Treatment of cancer by inhibiting ezh2 activity
|
|
WO2016149581A1
(en)
|
2015-03-19 |
2016-09-22 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
WO2016164463A1
(en)
|
2015-04-07 |
2016-10-13 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive x chromosome
|
|
CA2988816A1
(en)
*
|
2015-06-10 |
2016-12-15 |
Epizyme, Inc. |
Ezh2 inhibitors for treating lymphoma
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
MX2018002344A
(es)
|
2015-08-24 |
2018-07-06 |
Epizyme Inc |
Metodo para tratar el cancer.
|
|
TW201718598A
(zh)
|
2015-08-27 |
2017-06-01 |
美國禮來大藥廠 |
Ｅｚｈ２抑制劑
|
|
US10577350B2
(en)
|
2015-08-28 |
2020-03-03 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
EP4309738A3
(en)
|
2015-10-06 |
2024-07-17 |
Epizyme, Inc. |
Method of treating medulloblastoma with an ezh2 inhibitor
|
|
WO2017079738A1
(en)
|
2015-11-05 |
2017-05-11 |
Epizyme, Inc. |
Flow cytometry for monitoring histone h3 methylation status
|
|
DK3378859T3
(da)
*
|
2015-11-19 |
2020-01-20 |
Jiangsu Hengrui Medicine Co |
Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
|
|
EP3407978A4
(en)
|
2016-01-29 |
2020-01-15 |
Epizyme Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER
|
|
JP7174408B2
(ja)
|
2016-02-10 |
2022-11-17 |
ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ |
肝線維症のモデル系ならびにその作製および使用方法
|
|
CN120661674A
(zh)
|
2016-03-15 |
2025-09-19 |
奥莱松基因组股份有限公司 |
用于治疗实体瘤的lsd1抑制剂的组合
|
|
EP3442524A2
(en)
|
2016-04-15 |
2019-02-20 |
Novira Therapeutics Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
EP3445365A4
(en)
|
2016-04-22 |
2019-10-16 |
Dana-Farber Cancer Institute, Inc. |
EZH2 INHIBITORS AND USES THEREOF
|
|
CN105777718B
(zh)
*
|
2016-04-27 |
2019-03-19 |
上海应用技术学院 |
潜在ezh2小分子抑制剂及其合成方法
|
|
US10987353B2
(en)
|
2016-05-04 |
2021-04-27 |
The Wistar Institute Of Anatomy And Biology |
Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
|
|
US11147819B2
(en)
|
2016-06-17 |
2021-10-19 |
Epizyme, Inc. |
EZH2 inhibitors for treating cancer
|
|
WO2017221092A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
CN107573327B
(zh)
*
|
2016-07-05 |
2020-03-31 |
四川大学 |
吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
|
|
CN107573336B
(zh)
*
|
2016-07-05 |
2021-01-19 |
四川大学 |
苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途
|
|
CA3039059A1
(en)
|
2016-10-19 |
2018-04-26 |
Constellation Pharmaceuticals, Inc. |
Synthesis of inhibitors of ezh2
|
|
WO2018086590A1
(zh)
*
|
2016-11-11 |
2018-05-17 |
上海海雁医药科技有限公司 |
砜基取代的苯并杂环衍生物、其制法与医药上的用途
|
|
WO2018086589A1
(zh)
*
|
2016-11-11 |
2018-05-17 |
上海海雁医药科技有限公司 |
1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
|
|
EP3548032A2
(en)
|
2016-12-02 |
2019-10-09 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
US11311524B2
(en)
|
2017-01-19 |
2022-04-26 |
Daiichi Sankyo Company, Limited |
Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
|
|
US10266542B2
(en)
|
2017-03-15 |
2019-04-23 |
Mirati Therapeutics, Inc. |
EZH2 inhibitors
|
|
US11642346B2
(en)
|
2017-03-31 |
2023-05-09 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
WO2018231973A1
(en)
|
2017-06-13 |
2018-12-20 |
Epizyme, Inc. |
Inhibitors of ezh2 and methods of use thereof
|
|
EP3710057A1
(en)
|
2017-11-14 |
2020-09-23 |
Pfizer Inc |
Ezh2 inhibitor combination therapies
|
|
NZ766447A
(en)
|
2018-01-31 |
2021-12-24 |
Mirati Therapeutics Inc |
Prc2 inhibitors
|
|
CN110229151B
(zh)
*
|
2018-03-06 |
2021-09-10 |
上海海和药物研究开发股份有限公司 |
吲嗪类化合物、其制备方法及用途
|
|
EA202092171A1
(ru)
|
2018-03-14 |
2020-12-01 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Схема дозирования модулятора сборки капсида
|
|
EP3823671B1
(en)
|
2018-07-09 |
2024-02-07 |
Fondation Asile Des Aveugles |
Inhibition of prc2 subunits to treat eye disorders
|
|
AU2019312416B2
(en)
|
2018-07-27 |
2024-11-07 |
Evopoint Biosciences Co., Ltd. |
Polysubstituted benzene compound and preparation method and use thereof
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
CN113773304B
(zh)
*
|
2019-02-25 |
2023-03-10 |
江苏豪森药业集团有限公司 |
抗耐药抗肿瘤egfr抑制剂的制备方法
|
|
WO2020219448A1
(en)
|
2019-04-22 |
2020-10-29 |
Mirati Therapeutics, Inc. |
Naphthyridine derivatives as prc2 inhibitors
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
JP7541538B2
(ja)
|
2019-06-05 |
2024-08-28 |
ミラティ セラピューティクス，インク． |
癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
|
|
MD4003532T2
(ro)
|
2019-07-24 |
2025-01-31 |
Constellation Pharmaceuticals Inc |
Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
|
|
US20220298222A1
(en)
|
2019-08-22 |
2022-09-22 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
|
US12006232B2
(en)
|
2020-06-09 |
2024-06-11 |
Rapid Water Technology LLC |
Water processing apparatus
|
|
WO2022133046A2
(en)
*
|
2020-12-16 |
2022-06-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
CN113307765A
(zh)
*
|
2021-05-24 |
2021-08-27 |
上海泰坦科技股份有限公司 |
吡啶甲胺类化合物及其制备方法
|
|
WO2023025856A1
(en)
|
2021-08-25 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ezh2 inhibitors for the treatment of aortic valve stenosis
|
|
US20250049802A1
(en)
|
2021-12-14 |
2025-02-13 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
JP2025513620A
(ja)
|
2022-04-27 |
2025-04-24 |
第一三共株式会社 |
抗体－薬物コンジュゲートとｅｚｈ１阻害剤および／またはｅｚｈ２阻害剤との組合せ
|
|
CN117088810A
(zh)
*
|
2023-06-27 |
2023-11-21 |
海南医学院 |
3-氰基吡啶酮化合物的串联合成方法
|
|
CN117362277B
(zh)
*
|
2023-10-13 |
2025-02-11 |
沈阳药科大学 |
含咪唑啉酮结构的苯甲酰胺类化合物及其制备方法和应用
|
|
CN118745144A
(zh)
*
|
2024-06-21 |
2024-10-08 |
辽宁大学 |
新型ezh2抑制剂化合物及其制备方法和应用
|